The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
The Motley Fool
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
The Motley Fool
You must log in to post a comment.